Pleasure to be here and to meet you all in the room and also those watching online. I will spend some time introducing you to Isofol Medical and our project, primarily within the oncology field. We are staying in oncology, but shifting to another therapeutic area. To make it very short, we are a small listed biotech company focusing in on oncology, as I said, and our goal is basically to make today's and tomorrow's fundamental standard treatments for solid tumors more efficacious. We are currently conducting a phase I-B/II trial in metastatic colorectal cancer. As you have heard quite a few presentations already today, you will hear even more later on today and tomorrow. I will try to make this really short, brief, and as easily digestible as possible. So three things. First, what is the problem we address?
Why do we think it is worthwhile spending a lot of time, efforts on solving this particular problem? How then can we as a company really make a difference in this field? Starting on with this problem then, when it comes to solid tumors, there remains a large unmet medical need, and the patient outcomes are in general unsatisfactory, unfortunately, for most types of tumors. Survival rates are still, across the board, too low for advanced cancers. Basically, this comes down to the fact that there is a low response rate to the standard first-line treatments that these patients get, and as patients progresses through subsequent lines of treatment, all outcomes tend to get even worse. For Isofol, we have decided to attack this problem starting in colorectal cancer, metastatic colorectal cancer, to be more precise.
This is simply because this is a huge medical issue out there. It is the third most common cancer in the world. We have almost 2 million cases, new cases every year. It is the second leading cause of cancer-related death worldwide. For those patients who have metastases and advanced disease, the mortality rate is depressingly low. We are still, despite all the medical innovation going on in the field, looking at an 86% five-year mortality for advanced cancers. So clearly, a huge unmet medical need here. In this case, as in many other forms of solid tumors, we do see a low response rate to the standard first-line regimens. Well below 50% of patients respond to these treatments. As I said before, this holds true also in colorectal cancer. As patients progress through subsequent lines of treatment, outcome tend to get worse.
In the case of colorectal cancer, 90% of patients, the vast majority of patients, get the same standard chemotherapy regimen in first line. That is the case today, and that will remain the case tomorrow as well, despite all the exciting innovation that is going on in the field. There are many pharma companies interested in this particular indication, but this chemotherapy backbone is there to stay. The innovations that are coming into the market right now and in the coming decade are either adding on to the chemotherapy backbone or as subsequent lines of treatment. Our idea is that if we can improve and elevate response rates in the first-line setting, we can also achieve a great benefit to a very large group of patients. Remember, 90% of these patients get this treatment. It is clearly a very identifiable issue worth solving from a medical perspective.
Looking at it from a slightly different perspective, putting the commercial lens on, this high unmet medical need does translate into a compelling investment opportunity, if one like. There is a large patient group, as I said. The unmet medical need is undisputable. Competition in the field is limited, as most innovative efforts here are intended for use in later lines of treatment, or again, as an add-on to the chemotherapy backbone. Also, when it comes to payers, there is a high willingness to pay for improved outcomes in this condition, given the high mortality rates that I just presented. All of this translates into an interesting commercial opportunity that I will come back to later on in the presentation. How can we as a company make a difference with our drug candidate, arfolitixorin?
The drug is simply designed to replace folinic acid, one of the standard components in this basic chemotherapy regimen, and thereby enhancing the chemotherapy, in this case, it is called 5-FU, its ability to inhibit the target enzyme in the tumor cells, basically by making a stronger inhibitory complex with this target enzyme, that if not inhibited, it fuels tumor cell growth. If inhibited, tumors cannot grow anymore. That is simply how it works. There is already a drug of this kind approved on the market today. It is called leucovorin in most markets. This is a so-called prodrug. It has been used for several years, decades actually, out there, but it has one big disadvantage. It is a prodrug that requires multistep conversion and metabolization before it turns to this active substance that actually can exert its efficacy. That is in stark contrast to arfolitixorin, which is the active metabolite from the start.
So in essence, we are bypassing this whole need for metabolic conversion, meaning that we are direct-acting and can be efficacious instantly upon dosing, and also then bypass any possible inter-patient variability in the ability to convert leucovorin or folinic acid into the active substance. The aim, of course, is that this now will be translated into improved clinical outcomes. We are right now testing this drug in a phase Ib trial. I will talk soon about the promising data we have seen so far in that trial, and also a little bit about the platform of evidence we have when we entered this trial program we are currently in. So a few words about the preclinical evidence to date. We have done a lot of different experiments, most notably in organoids and in tumor homogenates.
What we have seen here is across the board when we do comparative studies that the efficacy in terms of cytotoxicity is higher than with regular folinic acid. That is a good sign. Second thing we have seen is a quite unique dose-response relationship. So the more of this drug we give, the more cytotoxic it gets, the more efficacy we can expect. This is not the case with today's folinic acid. It has been tested in clinical practice in different doses for decades, as I said. There is simply no relationship with the dose you give and the response you get. Clinicians have tested super high doses, super low doses. It seems it is basically plateauing at a certain efficacy level and does not get better than that. So we were very excited when we found this out in the organoid trials. There is also a fair amount of clinical evidence on the table already today.
We have seen already in resected tumors that the concentrations of this active substance is several fold higher when arfolitixorin has been given as compared to when leucovorin has been given. A good sign we actually penetrate tumor tissue better than apparently than today's standard of care. We have also performed a full-scale phase III program earlier in the company's history using a very low dose of the drug, and that showed that the drug was efficacious in the clinical setting at par with the standard of care. This low dose likely meant that we couldn't prove superiority in that particular trial. What we're doing now is a different trial with higher doses in an adjusted dosing regimen that's likely much more promising when it comes to efficacy. The trial we are now conducting looks like this basically. It's a classic dose escalation trial in phase I-B.
We are now testing the highest dose, 500 milligrams per square meter, and wrapping up that dose now as we speak. We are obviously excited that we were able to move all the way to the highest dose without any dose-limiting toxicities, given this dose-response relationship we saw in the preclinical models. Our aim now is to move on to phase II quite soon, as soon as we can wrap up phase I-B. Phase II is a larger trial conducted in multiple countries in Europe and also in Japan, with three arms basically testing two different doses of our drug to be in line with the FDA recommendations we have received versus one standard of care arm. We will have a direct comparison of this drug versus standard of care within the scope of this trial.
We had an interesting interim readout of the trial earlier this year, and we could there say that we had no dose-limiting side effects at any of the doses tested to that date. We also saw that all patients included in the trial actually had responded to treatment and exhibited tumor shrinkage, which we found extremely encouraging. Lastly, we also saw that a large proportion of these patients were actually responding in a way that they could be taken out of the study and considered for tumor resection. This was a route that would not be possible actually for these patients, given that they had a very difficult form of cancer. They become eligible for surgery during treatment, which was obviously a great outcome for patients. We are not working on this project alone.
We have a strong network of partners and clinical experts surrounding us and helping us out. We have handpicked the best experts we could find across the globe for this program, headed by Sebastian Stintzing, Professor at Charité in Berlin, who's also the lead investigator of the trial. We also already have a couple of key commercial partnerships in place. One of them with Merck, the German Merck, who owns and manufactures the drug substance that we then develop clinically and commercialize. We have a deep and ongoing patent IP collaboration with that company as well, and we have already secured large-scale manufacturing for these trials with Recipharm. We have a couple of commercial partnerships in place already in various parts of the world, most notably with Solasia Pharma in Japan, who are responsible not only for commercialization, but also clinical development in Japan.
Hence, the inclusion of Japanese patients in the phase II part of our program. I know that you want me to finish up. Just a few words on the commercial opportunity then.
Or I could just ask you a question about the commercial opportunity.
Well, thank you for the question. As it happens, I have a few slides on the topic, Cecilia.
Perfect.
Yes. Colorectal cancer is a growing and big market, as you can see, expected to amount to about $17 billion by 2030. Our potential in this market is also significant. Based on the extensive research we have done on the U.S. market, looking both at patient volumes and price levels we can command, we are actually looking at a billion-dollar opportunity in gross sales in the U.S. in the colorectal cancer indication alone. To this then, we can add additional markets outside of the U.S., obviously, and then also additional indications beyond colorectal cancer where the same type of basic chemotherapy regimen is used. Just to sum it up before you throw me off stage, Cecilia.
I wouldn't dare.
We are working in an area where the unmet medical need is undisputable. We have a high potential drug candidate that already has proven its efficacy in various trials, and we're now on the way to prove that even more in the phase II trial that's starting up shortly, and the commercial opportunity for us here is quite large.
Thank you, Petter. Just for Amelia then, does anyone have any questions in the room? Nope. Let's see. I'll pick one. Every time you and I talk, we talk about this, because you've also taken rights in autism. Do you just want to talk a little bit about the-
Yes
the thinking behind that?
That is an interesting question and not something we have spoken extensively about externally yet, actually. We have done here is basically secure our, shall we call it, strategic optionality in the field of autism, and more specifically, a type of autism caused by cerebral folate deficiency, where the levels in the brain are extremely low of this active substance that we happen to produce. It could be that our case in cancer also is actually valid in that specific indication. The folinic acid we intend to replace in cancer is actually being used for that specific indication and approved by the FDA for a subset of these patients in the U.S. We are sort of in a very exploratory stage, I would say, investigating right now to what extent we could potentially have an efficacy and some extra benefit in this field.
It is a very interesting opportunity, but I do not want to quantify it or say anything more than that at this point, but hope to be able to come back with more news next year about that indication.
Thank you so much, Petter.
Thank you.